静注用免疫グロブリン（IVIG）市場、シェア、規模、動向、産業分析レポート：投与経路別、成分別、用途別、エンドユーザー別、流通チャネル別、地域別、セグメント予測、2023年～2032年

Polaris market researchの最新調査によると、世界の静注用免疫グロブリン（IVIG）市場規模は2032年までに241億3,000万米ドルに達する見込みです。同レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

血漿分画技術と製造工程の進歩により、静注用免疫グロブリン（IVIG）製品はより安全で効果的なものとなっています。遺伝子組換え技術や精製方法のおかげで、免疫グロブリン製剤は高度に精製・濃縮されるようになり、副作用の可能性が減少し、より正確な治療が可能になりました。これらの開発により、原発性免疫不全症や特定の自己免疫疾患に対するIVIGの有効性が向上し、患者の予後を改善する新規免疫グロブリンベースの治療法を開発する機会が生まれました。現在進行中の調査により、慢性炎症性脱髄性多発神経炎、多巣性運動ニューロパチー、重症筋無力症などの神経疾患に対する新たな治療適応が明らかになりました。IVIGで治療される症状が拡大することで、免疫グロブリンをベースとした治療の市場ポテンシャルが広がり、より多くの人々に恩恵をもたらすことができます。

静注用免疫グロブリン（IVIG）の世界市場は、COVID-19の大流行により急増しました。2020年12月に実施された調査「COVID-19 in patients with primary and secondary immunodeficiency：英国の経験」によると、症候性二次性免疫不全症（SID）、原発性免疫不全症（PID）、自己炎症性疾患、C1インヒビター欠損症の患者100人のうち70％がSARS-CoV-2ウイルスに感染し、その59％が入院し、そのうち8％が命を落としました。このことは、免疫不全者がCOVID-19に感染するリスクが高いという事実を浮き彫りにしており、パンデミックに対抗するための静注用免疫グロブリン療法の需要増加が予想されます。

静注用免疫グロブリン（IVIG）市場レポートハイライト

予測期間中、IgGセグメントが最大となる見込みです。IgGは臨床試験で幅広く研究されており、その結果、医療分野で広く使用され、受け入れられています。これらの研究により、様々な自己免疫疾患、神経疾患、その他の免疫関連疾患の治療におけるIgGの有効性と安全性が実証されています。

2022年には、免疫不全症セグメントが最大の市場シェアを占めました。免疫不全症は、一次性（遺伝性）と二次性（後天性）の2種類に分類されます。一次性免疫不全症は一般的に遺伝的なもので、出生時から存在するが、二次性免疫不全症は感染症、薬剤、医療処置などの要因により、人生の後半に発症することがあります。

2022年には病院が最も高いシェアを占めています。病院薬局はIVIG療法を受ける患者をモニターし、ヘルスケア専門家と協力して患者の経過を追跡し、有害事象や反応があれば規制機関に報告します。

2022年、世界市場は北米地域が独占しました。北米には高度に発達したヘルスケアインフラがあり、同地域のIVIG市場の成長を支えているからです。がん患者数の増加とバクスター・インターナショナル社などの主要企業の存在により、効果的な薬剤が市場に導入されるケースが増えています。さらに、北米の大手製薬会社は研究開発、臨床試験、マーケティング戦略に多額の投資を行っており、これがIVIG市場の成長を後押ししています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の静注用免疫グロブリン（IVIG）市場に関する洞察

• 静注用免疫グロブリン（IVIG）- 業界スナップショット
• 静注用免疫グロブリン（IVIG）市場力学
  • 促進要因と機会
    • 免疫不全疾患に苦しむ人の数が増加
    • 免疫グロブリンベース治療の採用
  • 抑制要因と課題
    • 感染リスクが高く、市場の成長を妨げる
• PESTLE分析
• 静注用免疫グロブリン（IVIG）業界の動向
• COVID-19感染症の影響分析

第5章 世界の静注用免疫グロブリン（IVIG）市場、成分別

• 主な調査結果
• イントロダクション
• IgG
• IgA
• IgM
• IgE
• IgD

第6章 世界の静注用免疫グロブリン（IVIG）市場、投与経路別

• 主な調査結果
• イントロダクション
• 静脈内
• 皮下

第7章 世界の静注用免疫グロブリン（IVIG）市場、用途別

• 主な調査結果
• イントロダクション
• 低ガンマグロブリン血症
• 慢性炎症性脱髄性多発神経障害（CIDP）
• 免疫不全疾患
• 重症筋無力症
• 多巣性運動神経障害
• 特発性血小板減少性紫斑病（ITP）
• 炎症性筋症
• 特異的抗体欠損
• ギランバレー症候群

第8章 世界の静注用免疫グロブリン（IVIG）市場、エンドユーザー別

• 主な調査結果
• イントロダクション
• 病院
• 在宅医療
• 専門クリニック

第9章 世界の静注用免疫グロブリン（IVIG）市場、流通チャネル別

• 主な調査結果
• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第10章 世界の静注用免疫グロブリン（IVIG）市場、地域別

• 主な調査結果
• イントロダクション
  • 静注用免疫グロブリン（IVIG）市場評価、地域別、2019-2032年
• 静注用免疫グロブリン（IVIG）市場-北米
  • 北米：静注用免疫グロブリン（IVIG）市場、成分別、2019-2032年
  • 北米：静注用免疫グロブリン（IVIG）市場、エンドユーザー別、2019-2032年
  • 北米：静注用免疫グロブリン（IVIG）市場、投与経路別、2019-2032年
  • 北米：静注用免疫グロブリン（IVIG）市場、用途別、2019-2032年
  • 北米：静注用免疫グロブリン（IVIG）市場、流通チャネル別、2019-2032年
  • 静注用免疫グロブリン（IVIG）市場-米国
  • 静注用免疫グロブリン（IVIG）市場- カナダ
• 静注用免疫グロブリン（IVIG）市場- 欧州
  • 欧州：静注用免疫グロブリン（IVIG）市場、成分別、2019-2032年
  • 欧州：静注用免疫グロブリン（IVIG）市場、エンドユーザー別、2019-2032
  • 欧州：静注用免疫グロブリン（IVIG）市場、投与経路別、2019～2032年
  • 欧州：静注用免疫グロブリン（IVIG）市場、用途別、2019-2032年
  • 欧州：静注用免疫グロブリン（IVIG）市場、流通チャネル別、2019-2032年
  • 静注用免疫グロブリン（IVIG）市場- 英国
  • 静注用免疫グロブリン（IVIG）市場- フランス
  • 静注用免疫グロブリン（IVIG）市場- ドイツ
  • 静注用免疫グロブリン（IVIG）市場- イタリア
  • 静注用免疫グロブリン（IVIG）市場- スペイン
  • 静注用免疫グロブリン（IVIG）市場- オランダ
  • 静注用免疫グロブリン市場- ロシア
• 静注用免疫グロブリン（IVIG）市場- アジア太平洋
  • アジア太平洋：静注用免疫グロブリン（IVIG）市場、成分別、2019～2032年
  • アジア太平洋：静注用免疫グロブリン（IVIG）市場、エンドユーザー別、2019～2032年
  • アジア太平洋：静注用免疫グロブリン（IVIG）市場、投与経路別、2019～2032年
  • アジア太平洋：静注用免疫グロブリン（IVIG）市場、用途別、2019～2032年
  • アジア太平洋：静注用免疫グロブリン（IVIG）市場、流通チャネル別、2019-2032年
  • 静注用免疫グロブリン（IVIG）市場- 中国
  • 静注用免疫グロブリン（IVIG）市場- インド
  • 静注用免疫グロブリン（IVIG）市場- 日本
  • 静注用免疫グロブリン（IVIG）市場- マレーシア
  • 静注用免疫グロブリン（IVIG）市場- インドネシア
  • 静注用免疫グロブリン（IVIG）市場- 韓国
• 静注用免疫グロブリン（IVIG）市場-中東およびアフリカ
  • 中東およびアフリカ：静注用免疫グロブリン（IVIG）市場、成分別、2019～2032年
  • 中東およびアフリカ：静注用免疫グロブリン（IVIG）市場、エンドユーザー別、2019～2032年
  • 中東およびアフリカ：静注用免疫グロブリン（IVIG）市場、投与経路別、2019～2032年
  • 中東およびアフリカ：静注用免疫グロブリン（IVIG）市場、用途別、2019～2032年
  • 中東およびアフリカ：静注用免疫グロブリン（IVIG）市場、流通チャネル別、2019-2032年
  • 静注用免疫グロブリン（IVIG）市場- サウジアラビア
  • 静注用免疫グロブリン（IVIG）市場-UAE
  • 静注用免疫グロブリン（IVIG）市場- イスラエル
  • 静注用免疫グロブリン（IVIG）市場- 南アフリカ
• 静注用免疫グロブリン（IVIG）市場-ラテンアメリカ
  • ラテンアメリカ：静注用免疫グロブリン（IVIG）市場、成分別、2019-2032年
  • ラテンアメリカ：静注用免疫グロブリン（IVIG）市場、エンドユーザー別、2019-2032
  • ラテンアメリカ：静注用免疫グロブリン（IVIG）市場、投与経路別、2019-2032年
  • ラテンアメリカ：静注用免疫グロブリン（IVIG）市場、用途別、2019-2032年
  • ラテンアメリカ：静注用免疫グロブリン（IVIG）市場、流通チャネル別、2019-2032年
  • 静注用免疫グロブリン（IVIG）市場- メキシコ
  • 静注用免疫グロブリン（IVIG）市場- ブラジル
  • 静注用免疫グロブリン（IVIG）市場- アルゼンチン

第11章 競合情勢

• 拡張と買収の分析
  • 拡大
  • 買収
• 提携/協業/合意/公開

第12章 企業プロファイル

• Baxter International Inc.
• BDI Pharma Inc.
• Biotest AG
• China Biologics Products Inc.
• CSL Behring
• Grifols SA
• Kedrion Biopharma
• LFB Biotechnologies
• Octapharma AG

List of Tables

• Table 1 Global Intravenous immunoglobulin Market, by Component, by Region, 2019-2032 (USD Billion)
• Table 2 Global Intravenous immunoglobulin Market, by Route of Administration, by Region, 2019-2032 (USD Billion)
• Table 3 Global Intravenous immunoglobulin Market, by Application, by Region, 2019-2032 (USD Billion)
• Table 4 Global Intravenous immunoglobulin Market, by Distribution Channel, by Region, 2019-2032 (USD Billion)
• Table 5 Global Intravenous immunoglobulin Market, by End Users, by Region, 2019-2032 (USD Billion)
• Table 6 North America: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 7 North America: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 8 North America: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 9 North America: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 10 North America: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 11 U.S.: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 12 U.S.: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 13 U.S.: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 14 U.S.: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 15 U.S.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 16 Canada: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 17 Canada: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 18 Canada: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 19 Canada: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 20 Canada: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 21 Europe: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 22 Europe: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 23 Europe: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 24 Europe: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 25 Europe: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 26 Germany: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 27 Germany: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 28 Germany: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 29 Germany: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 30 Germany: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 31 France: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 32 France: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 33 France: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 34 France: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 35 France: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 36 UK: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 37 UK: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 38 UK: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 39 UK: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 40 UK: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 41 Italy: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 42 Italy: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 43 Italy: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 44 Italy: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 45 Italy: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 46 Netherlands: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 47 Netherlands: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 48 Netherlands: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 49 Netherlands: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 50 Netherlands: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 51 Spain: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 52 Spain: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 53 Spain: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 54 Spain: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 55 Spain: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 56 Russia: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 57 Russia: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 58 Russia: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 59 Russia: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 60 Russia: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 61 Asia Pacific: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 62 Asia Pacific: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 63 Asia Pacific: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 64 Asia Pacific: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 65 Asia Pacific: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 66 China: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 67 China: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 68 China: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 69 China: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 70 China: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 71 Japan: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 72 Japan: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 73 Japan: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 74 Japan: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 75 Japan: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 76 India: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 77 India: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 78 India: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 79 India: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 80 India: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 81 Indonesia: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 82 Indonesia: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 83 Indonesia: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 84 Indonesia: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 85 Indonesia: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 86 Malaysia: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 87 Malaysia: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 88 Malaysia: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 89 Malaysia: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 90 Malaysia: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 91 South Korea: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 92 South Korea: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 93 South Korea: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 94 South Korea: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 95 South Korea: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 96 Latin America: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 97 Latin America: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 98 Latin America: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 99 Latin America: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 100 Latin America: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 101 Brazil: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 102 Brazil: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 103 Brazil: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 104 Brazil: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 105 Brazil: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 106 Mexico: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 107 Mexico: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 108 Mexico: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 109 Mexico: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 110 Mexico: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 111 Argentina: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 112 Argentina: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 113 Argentina: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 114 Argentina: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 115 Argentina: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 116 Middle East & Africa: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 117 Middle East & Africa: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 118 Middle East & Africa: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 119 Middle East & Africa: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 120 Middle East & Africa: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 121 UAE: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 122 UAE: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 123 UAE: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 124 UAE: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 125 UAE: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 126 Saudi Arabia: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 127 Saudi Arabia: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 128 Saudi Arabia: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 129 Saudi Arabia: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 130 Saudi Arabia: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 131 South Africa: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 132 South Africa: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 133 South Africa: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 134 South Africa: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 135 South Africa: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• Table 136 Israel: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• Table 137 Israel: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 138 Israel: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• Table 139 Israel: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 140 Israel: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)

List of Figures

• Figure 1. Global Intravenous immunoglobulin Market, 2019-2032 (USD Billion)
• Figure 2. Integrated Ecosystem
• Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
• Figure 4. Market by Geography
• Figure 5. Porter's Five Forces
• Figure 6. Market by Component
• Figure 7. Global Intravenous immunoglobulin Market, by Component, 2021 & 2030 (USD Billion)
• Figure 8. Market by Route of Administration
• Figure 9. Global Intravenous immunoglobulin Market, by Route of Administration, 2021 & 2030 (USD Billion)
• Figure 10. Market by Application
• Figure 11. Global Intravenous immunoglobulin Market, by Application, 2021 & 2030 (USD Billion)
• Figure 12. Market by Distribution Channel
• Figure 13. Global Intravenous immunoglobulin Market, by Distribution Channel, 2021 & 2030 (USD Billion)
• Figure 14. Market by End Users
• Figure 15. Global Intravenous immunoglobulin Market, by End Users, 2021 & 2030 (USD Billion)

The global intravenous immunoglobulin market size is expected to reach USD 24.13 billion by 2032, according to a new study by Polaris market research. The report "Intravenous immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Intravenous, Subcutaneous); By Component; By Application; By End-user; By Distribution Channel; By Region; Segment Forecast, 2023- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Advancements in plasma fractionation techniques and manufacturing processes have made Intravenous Immunoglobulin (IVIG) products safer and more effective. Thanks to recombinant technologies and purification methods, immunoglobulin products are now highly refined and concentrated, which reduces the chance of adverse reactions and enables more precise therapies. These developments have improved the efficacy of IVIG for primary immune deficiencies, certain autoimmune disorders, and created opportunities for developing novel immunoglobulin-based treatments that can improve patient outcomes. Ongoing research has revealed new therapeutic indications for neurological conditions such as chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and myasthenia gravis. The expansion of symptoms treated with IVIG provides a wider market potential for immunoglobulin-based therapies, which can benefit more people.

The global market for intravenous immunoglobulin saw a surge due to the COVID-19 pandemic. Research conducted in December 2020, named "COVID-19 in patients with primary and secondary immunodeficiency: The U.K. experience", found that 70% out of 100 people with symptomatic secondary immunodeficiency (SID), primary immunodeficiency (PID), autoinflammatory diseases, and C1 inhibitor deficiency were infected with the SARS-CoV-2 virus and 59% of them were admitted to hospitals, with 8% of them losing their lives. This highlights the fact that immunocompromised individuals are at a higher risk of getting COVID-19, leading to an expected increase in the demand for intravenous immunoglobulin therapy to combat the pandemic.

Virtual trials offer numerous advantages, including remote data collection, increased participant engagement, and larger population inclusion. They minimize risks associated with in-person visits and reduce the burden on participants, coordinators, and investigators. By leveraging virtual methods, the clinical trials industry can overcome challenges, improve efficiency, and facilitate prompt and effective data collection.

Intravenous immunoglobulin Market Report Highlights

During the forecast period, the IgG segment is expected to be the largest. IgG has been extensively researched in clinical trials, which has resulted in its widespread use and acceptance in the medical field. These studies have demonstrated IgG's efficacy and safety in treating various autoimmune disorders, neurological conditions, and other immune-related diseases.

The immunodeficiency diseases segment held the largest market share in 2022. Immunodeficiency diseases can be categorized into two types: primary (inherited) and secondary (acquired). Primary immunodeficiencies are typically genetic and present from birth, while secondary immunodeficiencies can develop later in life due to factors such as infections, medications, or medical treatments.

Hospitals accounted for the highest share in 2022. Hospital pharmacies monitor patients receiving IVIG therapy, collaborate with healthcare professionals to track patient progress, and report any adverse events or reactions to regulatory bodies.

In 2022, the global market was dominated by the North America region. This is because North America has a highly advanced healthcare infrastructure that supports the growth of the IVIG market in the region. With a rising number of cancer patients and the presence of key players such as Baxter International Inc., effective drugs are increasingly being introduced into the market. Furthermore, major pharmaceutical companies in North America invest heavily in research and development, clinical trials, and marketing strategies, which in turn drives the growth of the IVIG market.

The global key market players include: Baxter International Inc., BDI Pharma Inc., Biotest AG, China Biologics Products Inc., CSL Behring, Grifols SA, Kedrion Biopharma, LFB Biotechnologies, Octapharma AG

Polaris market research has segmented the Intravenous immunoglobulin market report based on component, route of administration, application, end-users, distribution channel and region:

Intravenous immunoglobulin, Component Outlook (Revenue - USD Billion, 2019 - 2032)

• IGG
• IGA
• IGM
• IGE
• IGD

Intravenous immunoglobulin, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

• Intravenous
• Subcutaneous

Intravenous immunoglobulin, Application Outlook (Revenue - USD Billion, 2019 - 2032)

• Hypogammaglobulinemia
• Chronic Inflammatory demyelinating polyneuropathy (CIDP)
• Immunodeficiency diseases
• Myasthenia Gravis
• Multifocal motor neuropathy
• Idiopathic thrombocytopenic purpura (ITP)
• Inflammatory myopathies
• Specific antibody deficiency
• Guillain-Barre syndrome

Intravenous immunoglobulin, End-Users Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospitals
• Homecare
• Specialty Clinics

Intravenous immunoglobulin, Distribution channels Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies

Intravenous immunoglobulin, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Latin America
• Argentina
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Intravenous Immunoglobulin Market Insights

• 4.1. Intravenous immunoglobulin - Industry Snapshot
• 4.2. Intravenous immunoglobulin Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. The number of people suffering from immunodeficiency disorders is on the rise.to drive the market growth
    • 4.2.1.2. Adoption of immunoglobulin-based therapies, drive the market
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High risk of transmission, hinder the market growth
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Intravenous immunoglobulin Industry Trends
• 4.6. COVID-19 Impact Analysis

5. Global Intravenous immunoglobulin Market, by Component

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Intravenous Immunoglobulin Market, by Component, 2019-2032 (USD Billion)
• 5.3. IGG
  • 5.3.1. Global Intravenous Immunoglobulin Market, by IGG, by Region, 2019-2032 (USD Billion)
• 5.4. IGA
  • 5.4.1. Global Intravenous Immunoglobulin Market, by IGA, by Region, 2019-2032 (USD Billion)
• 5.5. IGM
  • 5.5.1. Global Intravenous Immunoglobulin Market, by IGM, by Region, 2019-2032 (USD Billion)
• 5.6. IGE
  • 5.6.1. Global Intravenous Immunoglobulin Market, by IGE, by Region, 2019-2032 (USD Billion)
• 5.7. IGD
  • 5.7.1. Global Intravenous Immunoglobulin Market, by IGD, by Region, 2019-2032 (USD Billion)

6. Global Intravenous immunoglobulin Market, by Route of Administration

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
• 6.3. Intravenous
  • 6.3.1. Global Intravenous immunoglobulin Market, by Intravenous, by Region, 2019-2032 (USD Billion)
• 6.4. Subcutaneous
  • 6.4.1. Global Intravenous immunoglobulin Market, by Subcutaneous, by Region, 2019-2032 (USD Billion)

7. Global Intravenous immunoglobulin Market, by Application

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
• 7.3. Hypogammaglobulinemia
  • 7.3.1. Global Intravenous immunoglobulin Market, by Hypogammaglobulinemia, by Region, 2019-2032 (USD Billion)
• 7.4. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
  • 7.4.1. Global Intravenous immunoglobulin Market, by Chronic Inflammatory demyelinating polyneuropathy (CIDP), by Region, 2019-2032 (USD Billion)
• 7.5. Immunodeficiency diseases
  • 7.5.1. Global Intravenous immunoglobulin Market, by Immunodeficiency diseases, by Region, 2019-2032 (USD Billion)
• 7.6. Myasthenia Gravis
  • 7.6.1. Global Intravenous immunoglobulin Market, by Myasthenia Gravis, by Region, 2019-2032 (USD Billion)
• 7.7. Multifocal motor neuropathy
  • 7.7.1. Global Intravenous immunoglobulin Market, by Multifocal motor neuropathy, by Region, 2019-2032 (USD Billion)
• 7.8. Idiopathic thrombocytopenic purpura (ITP)
  • 7.8.1. Global Intravenous immunoglobulin Market, by Idiopathic thrombocytopenic purpura (ITP), by Region, 2019-2032 (USD Billion)
• 7.9. Inflammatory myopathies
  • 7.9.1. Global Intravenous immunoglobulin Market, by Inflammatory myopathies, by Region, 2019-2032 (USD Billion)
• 7.10. Specific antibody deficiency
  • 7.10.1. Global Intravenous immunoglobulin Market, by Specific antibody deficiency, by Region, 2019-2032 (USD Billion)
• 7.11. Guillain-Barre syndrome
  • 7.11.1. Global Intravenous immunoglobulin Market, by Guillain-Barre syndrome, by Region, 2019-2032 (USD Billion)

8. Global Intravenous immunoglobulin Market, by End Users

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
• 8.3. Hospitals
  • 8.3.1. Global Intravenous immunoglobulin Market, by Hospitals, by Region, 2019-2032 (USD Billion)
• 8.4. Homecare
  • 8.4.1. Global Intravenous immunoglobulin Market, by Homecare, by Region, 2019-2032 (USD Billion)
• 8.5. Specialty Clinics
  • 8.5.1. Global Intravenous immunoglobulin Market, by Specialty Clinics, by Region, 2019-2032 (USD Billion)

9. Global Intravenous immunoglobulin Market, by Distribution Channel

• 9.1. Key Findings
• 9.2. Introduction
  • 9.2.1. Global Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• 9.3. Hospital Pharmacy
  • 9.3.1. Global Intravenous immunoglobulin Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Billion)
• 9.4. Retail Pharmacy
  • 9.4.1. Global Intravenous immunoglobulin Market, by Retail Pharmacy, by Region, 2019-2032 (USD Billion)
• 9.5. Online Pharmacies
  • 9.5.1. Global Intravenous immunoglobulin Market, by Online Pharmacies, by Region, 2019-2032 (USD Billion)

10. Global Intravenous immunoglobulin Market, by Geography

• 10.1. Key findings
• 10.2. Introduction
  • 10.2.1. Intravenous immunoglobulin Market Assessment, By Geography, 2019-2032 (USD Billion)
• 10.3. Intravenous immunoglobulin Market - North America
  • 10.3.1. North America: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
  • 10.3.2. North America: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
  • 10.3.3. North America: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
  • 10.3.4. North America: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 10.3.5. North America: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.3.6. Intravenous immunoglobulin Market - U.S.
    • 10.3.6.1. U.S.: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.3.6.2. U.S.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.3.6.3. U.S.: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.3.6.4. U.S.: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.3.6.5. U.S.: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.3.7. Intravenous immunoglobulin Market - Canada
    • 10.3.7.1. Canada: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.3.7.2. Canada.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.3.7.3. Canada: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.3.7.4. Canada: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.3.7.5. Canada: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• 10.4. Intravenous immunoglobulin Market - Europe
  • 10.4.1. Europe: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
  • 10.4.2. Europe.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
  • 10.4.3. Europe: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
  • 10.4.4. Europe: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 10.4.5. Europe: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.4.6. Intravenous immunoglobulin Market - UK
    • 10.4.6.1. UK: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.4.6.2. UK.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.4.6.3. UK: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.4.6.4. UK: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.4.6.5. UK: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.4.7. Intravenous immunoglobulin Market - France
    • 10.4.7.1. France: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.4.7.2. France.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.4.7.3. France: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.4.7.4. France: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.4.7.5. France: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.4.8. Intravenous immunoglobulin Market - Germany
    • 10.4.8.1. Germany: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.4.8.2. Germany.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.4.8.3. Germany: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.4.8.4. Germany: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.4.8.5. Germany: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.4.9. Intravenous immunoglobulin Market - Italy
    • 10.4.9.1. Italy: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.4.9.2. Italy.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.4.9.3. Italy: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.4.9.4. Italy: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.4.9.5. Italy: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.4.10. Intravenous immunoglobulin Market - Spain
    • 10.4.10.1. Spain: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.4.10.2. Spain.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.4.10.3. Spain: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.4.10.4. Spain: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.4.10.5. Spain: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.4.11. Intravenous immunoglobulin Market - Netherlands
    • 10.4.11.1. Netherlands: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.4.11.2. Netherlands.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.4.11.3. Netherlands: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.4.11.4. Netherlands: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.4.11.5. Netherlands: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.4.12. Intravenous immunoglobulin Market - Russia
    • 10.4.12.1. Russia: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.4.12.2. Russia.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.4.12.3. Russia: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.4.12.4. Russia: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.4.12.5. Russia: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• 10.5. Intravenous immunoglobulin Market - Asia Pacific
  • 10.5.1. Asia Pacific: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
  • 10.5.2. Asia Pacific.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
  • 10.5.3. Asia Pacific: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
  • 10.5.4. Asia Pacific: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 10.5.5. Asia Pacific: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.5.6. Intravenous immunoglobulin Market - China
    • 10.5.6.1. China: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.5.6.2. China.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.5.6.3. China: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.5.6.4. China: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.5.6.5. China: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.5.7. Intravenous immunoglobulin Market - India
    • 10.5.7.1. India: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.5.7.2. India.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.5.7.3. India: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.5.7.4. India: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.5.7.5. India: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.5.8. Intravenous immunoglobulin Market - Japan
    • 10.5.8.1. Japan: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.5.8.2. Japan.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.5.8.3. Japan: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.5.8.4. Japan: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.5.8.5. Japan: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.5.9. Intravenous immunoglobulin Market - Malaysia
    • 10.5.9.1. Malaysia: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.5.9.2. Malaysia.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.5.9.3. Malaysia: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.5.9.4. Malaysia: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.5.9.5. Malaysia: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.5.10. Intravenous immunoglobulin Market - Indonesia
    • 10.5.10.1. Indonesia: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.5.10.2. Indonesia.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.5.10.3. Indonesia: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.5.10.4. Indonesia: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.5.10.5. Indonesia: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.5.11. Intravenous immunoglobulin Market - South Korea
    • 10.5.11.1. South Korea: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.5.11.2. South Korea.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.5.11.3. South Korea: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.5.11.4. South Korea: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.5.11.5. South Korea: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• 10.6. Intravenous immunoglobulin Market - Middle East & Africa
  • 10.6.1. Middle East & Africa: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
  • 10.6.2. Middle East & Africa: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
  • 10.6.3. Middle East & Africa: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
  • 10.6.4. Middle East & Africa: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 10.6.5. Middle East & Africa: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.6.6. Intravenous immunoglobulin Market - Saudi Arabia
    • 10.6.6.1. Saudi Arabia: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.6.6.2. Saudi Arabia.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.6.6.3. Saudi Arabia: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.6.6.4. Saudi Arabia: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.6.6.5. Saudi Arabia: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.6.7. Intravenous immunoglobulin Market - UAE
    • 10.6.7.1. UAE: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.6.7.2. UAE.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.6.7.3. UAE: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.6.7.4. UAE: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.6.7.5. UAE: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.6.8. Intravenous immunoglobulin Market - Israel
    • 10.6.8.1. Israel: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.6.8.2. Israel.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.6.8.3. Israel: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.6.8.4. Israel: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.6.8.5. Israel: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.6.9. Intravenous immunoglobulin Market - South Africa
    • 10.6.9.1. South Africa: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.6.9.2. South Africa.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.6.9.3. South Africa: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.6.9.4. South Africa: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.6.9.5. South Africa: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
• 10.7. Intravenous immunoglobulin Market - Latin America
  • 10.7.1. Latin America: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
  • 10.7.2. Latin America.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
  • 10.7.3. Latin America: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
  • 10.7.4. Latin America: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 10.7.5. Latin America: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.7.6. Intravenous immunoglobulin Market - Mexico
    • 10.7.6.1. Mexico: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.7.6.2. Mexico.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.7.6.3. Mexico: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.7.6.4. Mexico: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.7.6.5. Mexico: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.7.7. Intravenous immunoglobulin Market - Brazil
    • 10.7.7.1. Brazil: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.7.7.2. Brazil.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.7.7.3. Brazil: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.7.7.4. Brazil: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.7.7.5. Brazil: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 10.7.8. Intravenous immunoglobulin Market - Argentina
    • 10.7.8.1. Argentina: Intravenous immunoglobulin Market, by Component, 2019-2032 (USD Billion)
    • 10.7.8.2. Argentina.: Intravenous immunoglobulin Market, by End Users, 2019-2032 (USD Billion)
    • 10.7.8.3. Argentina: Intravenous immunoglobulin Market, by Route of Administration, 2019-2032 (USD Billion)
    • 10.7.8.4. Argentina: Intravenous immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 10.7.8.5. Argentina: Intravenous immunoglobulin Market, by Distribution Channel, 2019-2032 (USD Billion)

11. Competitive Landscape

• 11.1. Expansion and Acquisition Analysis
  • 11.1.1. Expansion
  • 11.1.2. Acquisitions
• 11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

• 12.1. Baxter International Inc.
  • 12.1.1. Company Overview
  • 12.1.2. Financial Performance
  • 12.1.3. Product Benchmarking
  • 12.1.4. Recent Development
• 12.2. BDI Pharma Inc.
  • 12.2.1. Company Overview
  • 12.2.2. Financial Performance
  • 12.2.3. Product Benchmarking
  • 12.2.4. Recent Development
• 12.3. Biotest AG
  • 12.3.1. Company Overview
  • 12.3.2. Financial Performance
  • 12.3.3. Product Benchmarking
  • 12.3.4. Recent Development
• 12.4. China Biologics Products Inc.
  • 12.4.1. Company Overview
  • 12.4.2. Financial Performance
  • 12.4.3. Product Benchmarking
  • 12.4.4. Recent Development
• 12.5. CSL Behring
  • 12.5.1. Company Overview
  • 12.5.2. Financial Performance
  • 12.5.3. Product Benchmarking
  • 12.5.4. Recent Development
• 12.6. Grifols SA
  • 12.6.1. Company Overview
  • 12.6.2. Financial Performance
  • 12.6.3. Product Benchmarking
  • 12.6.4. Recent Development
• 12.7. Kedrion Biopharma
  • 12.7.1. Company Overview
  • 12.7.2. Financial Performance
  • 12.7.3. Product Benchmarking
  • 12.7.4. Recent Development
• 12.8. LFB Biotechnologies
  • 12.8.1. Company Overview
  • 12.8.2. Financial Performance
  • 12.8.3. Product Benchmarking
  • 12.8.4. Recent Development
• 12.9. Octapharma AG
  • 12.9.1. Company Overview
  • 12.9.2. Financial Performance
  • 12.9.3. Product Benchmarking
  • 12.9.4. Recent Development